, Columnist
Indian Pharma Exits the Trauma Room
Now they just have to survive Dr. Trump's trade prescriptions.
This article is for subscribers only.
India's generic drugmaking industry is getting wheeled out of intensive care. But is it really going home?
The U.S. Food and Drug Administration this week lifted the import ban on a factory that Mumbai-based Sun Pharmaceutical Industries Ltd. inherited as part of its takeover of Ranbaxy Laboratories Ltd. The plant, in Punjab state, became the third owned by Ranbaxy to be shut out of the U.S. when the FDA imposed the prohibition in September 2013, causing the Indian company to lose a third of its market value in one day.